

## Endocrine functions of bone in mineral metabolism regulation

L. Darryl Quarles

*J Clin Invest.* 2009;119(2):421-421. <https://doi.org/10.1172/JCI36479C1>.

### Corrigendum

Original citation: *J. Clin. Invest.* 118:3820-3828 (2008). doi:10.1172/JCI36479. Citation for this corrigendum: *J. Clin. Invest.* 119:421 (2009). doi:10.1172/JCI36479C1. The author wishes to clarify that heterozygous mutations in the SCL34A1 gene have been described in only 2 individuals with nephrolithiasis, renal phosphate loss, and hypophosphatemia (Prié, D., et al. 2002. Nephrolithiasis and osteoporosis associated with hypophosphatemia caused by mutations in the type 2a sodium-phosphate cotransporter. *N. Engl. J. Med.* 347:983–991). After acceptance of this *JCI Science in Medicine* article for publication, 3 distinct mutations in NHERF1 were reported in 7 patients with renal phosphate loss and nephrolithiasis and/or bone demineralization (Karim, Z., et al. 2008. NHERF1 mutations and responsiveness of renal parathyroid hormone. *N. Engl. J. Med.* 359:1128–1135).

**Find the latest version:**

<https://jci.me/36479C1/pdf>





## Corrigendum

### **Loss of PIP5KI $\gamma$ , unlike other PIP5KI isoforms, impairs the integrity of the membrane cytoskeleton in murine megakaryocytes**

Yanfeng Wang, Rustem I. Litvinov, Xinsheng Chen, Tami L. Bach, Lurong Lian, Brian G. Petrich, Susan J. Monkley, Yasunori Kanaho, David R. Critchley, Takehiko Sasaki, Morris J. Birnbaum, John W. Weisel, John Hartwig, and Charles S. Abrams

Original citation: *J. Clin. Invest.* **118**:812–819 (2008). doi:10.1172/JCI34239.

Citation for this corrigendum: *J. Clin. Invest.* **119**:421 (2009). doi:10.1172/JCI34239C1.

During the preparation of the manuscript, Yasunori Kanaho's name was inadvertently omitted from the author list. The correct author list appears above, and Kanaho's affiliation information appears below.

Department of Physiological Chemistry, Graduate School of Comprehensive Human Sciences and Institute of Basic Medical Sciences, University of Tsukuba, Tsukuba, Japan.

The authors regret the error.

## Corrigendum

### **Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake**

Markus Loeffler, Jörg A. Krüger, Andreas G. Niethammer, and Ralph A. Reisfeld

Original citation: *J. Clin. Invest.* **116**:1955–1962 (2006). doi:10.1172/JCI26532.

Citation for this corrigendum: *J. Clin. Invest.* **119**:421 (2009). doi:10.1172/JCI26532C1.

In Acknowledgments, the Department of Defense grant to R.A. Reisfeld was cited incorrectly. The correct grant number is BCO50141.

The authors regret the error.

## Corrigendum

### **Endocrine functions of bone in mineral metabolism regulation**

L. Darryl Quarles

Original citation: *J. Clin. Invest.* **118**:3820–3828 (2008). doi:10.1172/JCI36479.

Citation for this corrigendum: *J. Clin. Invest.* **119**:421 (2009). doi:10.1172/JCI36479C1.

The author wishes to clarify that heterozygous mutations in the *SCL34A1* gene have been described in only 2 individuals with nephrolithiasis, renal phosphate loss, and hypophosphatemia (Prié, D., et al. 2002. Nephrolithiasis and osteoporosis associated with hypophosphatemia caused by mutations in the type 2a sodium-phosphate cotransporter. *N. Engl. J. Med.* **347**:983–991).

After acceptance of this *JCI* Science in Medicine article for publication, 3 distinct mutations in *NHERF1* were reported in 7 patients with renal phosphate loss and nephrolithiasis and/or bone demineralization (Karim, Z., et al. 2008. *NHERF1* mutations and responsiveness of renal parathyroid hormone. *N. Engl. J. Med.* **359**:1128–1135).